- Home
- Publications
- Publication Search
- Publication Details
Title
MicroRNA-mediated drug resistance in ovarian cancer
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2017-06-19
DOI
10.1002/jcp.26060
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ovarian cancer stem cells: still an elusive entity?
- (2017) Michela Lupia et al. Molecular Cancer
- miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway
- (2017) S-L Tung et al. Oncogenesis
- Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer
- (2017) Kira Philipsen Prahm et al. PLoS One
- HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells
- (2016) H. Sadik et al. CANCER RESEARCH
- DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme
- (2016) Zachary D. Nagel et al. CANCER RESEARCH
- Current Challenges in Cancer Treatment
- (2016) Jon Zugazagoitia et al. CLINICAL THERAPEUTICS
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
- (2016) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
- (2016) Chee-Seng Tan et al. LUNG CANCER
- Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer
- (2016) J.-Y. Kim et al. MOLECULAR CANCER RESEARCH
- The cellular origins of drug resistance in cancer
- (2016) Geoffrey R Oxnard NATURE MEDICINE
- Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth
- (2016) Y Wang et al. ONCOGENE
- Emerging therapeutic targets in metastatic progression: A focus on breast cancer
- (2016) Zhuo Li et al. PHARMACOLOGY & THERAPEUTICS
- MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1
- (2016) Di-di Wu et al. TUMOR BIOLOGY
- Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1 -Mutant Ovarian Cancer
- (2016) Young Eun Choi et al. Cell Reports
- New insights in the pathophysiology of ovarian cancer and implications for screening and prevention
- (2015) Farr R. Nezhat et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm
- (2015) Elias Jabbour et al. Clinical Lymphoma Myeloma & Leukemia
- ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
- (2015) Haigang Cui et al. CURRENT DRUG TARGETS
- The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
- (2015) Rishil J. Kathawala et al. DRUG RESISTANCE UPDATES
- The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells
- (2015) Ryan Charles Pink et al. GYNECOLOGIC ONCOLOGY
- Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
- (2015) Guoyan Liu et al. JNCI-Journal of the National Cancer Institute
- MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1
- (2015) Kai-Xuan Sun et al. Journal of Ovarian Research
- miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
- (2015) Nicola Amodio et al. Oncotarget
- MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1
- (2015) Shaohua Xu et al. Oncotarget
- Overcoming Multidrug Resistance in Cancer Stem Cells
- (2015) Karobi Moitra Biomed Research International
- Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
- (2015) Guoyan Liu et al. JNCI-Journal of the National Cancer Institute
- MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling
- (2015) Ying Fang et al. Journal of Biological Research-Thessaloniki
- MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells
- (2015) Ningwei Li et al. PLoS One
- DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma
- (2015) Nicola Amodio et al. Oncotarget
- Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
- (2014) Hongping Xia et al. CURRENT MEDICINAL CHEMISTRY
- The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer
- (2014) John K. Chan et al. GYNECOLOGIC ONCOLOGY
- MicroRNA 130b enhances drug resistance in human ovarian cancer cells
- (2014) Can Zong et al. TUMOR BIOLOGY
- microRNA 490-3P enhances the drug-resistance of human ovarian cancer cells
- (2014) Shuo Chen et al. Journal of Ovarian Research
- Drug Resistance in Cancer: An Overview
- (2014) Genevieve Housman et al. Cancers
- Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly
- (2013) X. Zhang et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer
- (2013) J H Huh et al. BRITISH JOURNAL OF CANCER
- miRNA profiling of cancer
- (2013) Gianpiero Di Leva et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Downregulation ofmiR-29contributes to cisplatin resistance of ovarian cancer cells
- (2013) Pei-Ning Yu et al. INTERNATIONAL JOURNAL OF CANCER
- MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells
- (2013) Yu-mei Rao et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition
- (2013) Chaoyang Sun et al. JNCI-Journal of the National Cancer Institute
- A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis
- (2013) A. Vecchione et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival
- (2012) Erhong Meng et al. CLINICAL & EXPERIMENTAL METASTASIS
- Delivering the promise of miRNA cancer therapeutics
- (2012) Diane M. Pereira et al. DRUG DISCOVERY TODAY
- MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells
- (2012) Weiwei Cheng et al. FEBS Journal
- Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells
- (2012) Xin Fu et al. FEBS LETTERS
- miRNAs and cancer: An epigenetics view
- (2012) Marcos Malumbres MOLECULAR ASPECTS OF MEDICINE
- miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells
- (2012) M T M van Jaarsveld et al. ONCOGENE
- Combination Therapy with Gossypol Reveals Synergism against Gemcitabine Resistance in Cancer Cells with High BCL-2 Expression
- (2012) Foong Ying Wong et al. PLoS One
- Anti-P-glycoprotein conjugated nanoparticles for targeting drug delivery in cancer treatment
- (2011) Pantiwa Iangcharoen et al. ARCHIVES OF PHARMACAL RESEARCH
- Akt2 Regulates All Akt Isoforms and Promotes Resistance to Hypoxia through Induction of miR-21 upon Oxygen Deprivation
- (2011) C. Polytarchou et al. CANCER RESEARCH
- microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C
- (2011) Elisa Penna et al. EMBO JOURNAL
- Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1
- (2011) Chun Yang et al. GYNECOLOGIC ONCOLOGY
- Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells
- (2011) Ran Qiang et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1
- (2011) Benjamin Boyerinas et al. INTERNATIONAL JOURNAL OF CANCER
- MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance
- (2011) G. Ye et al. JOURNAL OF CELL SCIENCE
- miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1
- (2011) Fanfei Kong et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- The emerging role of miR-200 family of MicroRNAs in epithelial-mesenchymal transition and cancer metastasis
- (2011) Manav Korpal et al. RNA Biology
- The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
- (2010) Robert J. Kurman et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Sp1/NFκB/HDAC/miR-29b Regulatory Network in KIT-Driven Myeloid Leukemia
- (2010) Shujun Liu et al. CANCER CELL
- Molecular Profiling Uncovers a p53-Associated Role for MicroRNA-31 in Inhibiting the Proliferation of Serous Ovarian Carcinomas and Other Cancers
- (2010) C. J. Creighton et al. CANCER RESEARCH
- Frequent Downregulation of miR-34 Family in Human Ovarian Cancers
- (2010) D. C. Corney et al. CLINICAL CANCER RESEARCH
- The miR-200 family controls -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients
- (2010) S. Leskela et al. ENDOCRINE-RELATED CANCER
- MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein
- (2010) Lou INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer
- (2010) Ankur K. Nagaraja et al. MOLECULAR ENDOCRINOLOGY
- MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
- (2009) R. Garzon et al. BLOOD
- mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
- (2009) S. Mabuchi et al. CLINICAL CANCER RESEARCH
- Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis
- (2009) Tetsuya Ueda et al. LANCET ONCOLOGY
- Repertoire of microRNAs in Epithelial Ovarian Cancer as Determined by Next Generation Sequencing of Small RNA cDNA Libraries
- (2009) Stacia K. Wyman et al. PLoS One
- Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
- (2008) S. Zhang et al. CANCER RESEARCH
- MicroRNA Microarray Identifies Let-7i as a Novel Biomarker and Therapeutic Target in Human Epithelial Ovarian Cancer
- (2008) N. Yang et al. CANCER RESEARCH
- MicroRNA Expression Profiling in Human Ovarian Cancer: miR-214 Induces Cell Survival and Cisplatin Resistance by Targeting PTEN
- (2008) H. Yang et al. CANCER RESEARCH
- MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth
- (2008) Julia Schultz et al. CELL RESEARCH
- The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional RepressorsZEB1andZEB2
- (2008) Manav Korpal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian Cancer
- (2008) Neetu Dahiya et al. PLoS One
- Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer
- (2008) L. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- let-7 microRNAs in development, stem cells and cancer
- (2008) Ingo Büssing et al. TRENDS IN MOLECULAR MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More